Home > Market > Market Stats >  Gland Pharma

Gland Pharma

Sector: Biotechnology & Drugs
Powered by
2130.00 -3.85 (-0.18%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 2121.9
Today’s High 2151.85
52 Week Low 2040.7
52 Week High 4074.0

Key Metrics

  • Market Cap (In Cr) 35109.93
  • Beta -
  • Div. Yield (%) 0
  • P/B 4.89
  • TTM P/E 40.72
  • Peg Ratio 4.26
  • Sector P/E 25.43
  • D/E -
  • Open Price 2130.15
  • Prev Close 2133.85
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    3.47%
  • 3 Months
    -15.61%
  • 6 Month
    -36.96%
  • YTD
    -44.83%
  • 1 Year
    -45.03%
Risk Meter
  • 32% Low risk
  • 32% Moderate risk
  • 32% Balanced Risk
  • 32% High risk
  • 32% Extreme risk
Recos
17 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 2
  • Sell
  • 2
  • Hold
  • 1
  • Buy
  • 3
  • Strong Buy
  • 9

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 4400.71
  • Selling/ General/ Admin Expenses Total
  • 694.61
  • Depreciation/ Amortization
  • 110.3
  • Other Operating Expenses Total
  • 3.78
  • Total Operating Expense
  • 3000.67
  • Operating Income
  • 1400.03
  • Net Income Before Taxes
  • 1618.55
  • Net Income
  • 1211.66
  • Diluted Normalized EPS
  • 73.65
  • Period
  • 2021
  • Total Revenue
  • 3462.88
  • Selling/ General/ Admin Expenses Total
  • 590.16
  • Depreciation/ Amortization
  • 98.78
  • Other Operating Expenses Total
  • 0.12
  • Total Operating Expense
  • 2259.43
  • Operating Income
  • 1203.45
  • Net Income Before Taxes
  • 1334.81
  • Net Income
  • 996.96
  • Diluted Normalized EPS
  • 62.99
  • Period
  • 2020
  • Total Revenue
  • 2633.24
  • Selling/ General/ Admin Expenses Total
  • 514.31
  • Depreciation/ Amortization
  • 94.59
  • Other Operating Expenses Total
  • 4.31
  • Total Operating Expense
  • 1772.36
  • Operating Income
  • 860.88
  • Net Income Before Taxes
  • 992.87
  • Net Income
  • 772.86
  • Diluted Normalized EPS
  • 46.5
  • Period
  • 2019
  • Total Revenue
  • 2044.2
  • Selling/ General/ Admin Expenses Total
  • 432.64
  • Depreciation/ Amortization
  • 82.12
  • Other Operating Expenses Total
  • 1.04
  • Total Operating Expense
  • 1439.82
  • Operating Income
  • 604.38
  • Net Income Before Taxes
  • 686.28
  • Net Income
  • 451.86
  • Diluted Normalized EPS
  • 28.48
  • Period
  • 2018
  • Total Revenue
  • 1622.89
  • Selling/ General/ Admin Expenses Total
  • 340.2
  • Depreciation/ Amortization
  • 78.37
  • Other Operating Expenses Total
  • 1.62
  • Total Operating Expense
  • 1165.98
  • Operating Income
  • 456.92
  • Net Income Before Taxes
  • 501.46
  • Net Income
  • 321.05
  • Diluted Normalized EPS
  • 21.33
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day2085.45
  • 10 Day2120.5
  • 20 Day2250.73
  • 50 Day2303.85
  • 100 Day2518.11
  • 300 Day2988.35

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap
  • Biocon
  • 298.45
  • 6.5
  • 2.23
  • 410.5
  • 273.65
  • 35581.35
  • Lupin
  • 742.55
  • 19.95
  • 2.76
  • 979.25
  • 583.05
  • 33748.22

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 20-Jul-22
  • Quarterly Results
  • 19-May-22
  • Audited Results
  • 21-Jan-22
  • Quarterly Results
  • 22-Oct-21
  • Quarterly Results
  • 21-Jul-21
  • Quarterly Results
  • 17-May-21
  • Audited Results
  • 22-Jan-21
  • Quarterly Results

Company Profile

ABOUT Gland Pharma

  • Industry Biotechnology & Drugs
  • ISIN INE068V01023
  • BSE Code 543245
  • NSE Code GLAND

Gland Pharma Limited is an India-based company that manufactures small volume parenterals (SVPs). The Company provides a range of injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions and ophthalmic solutions. It provides contract development and manufacturing services, such as evaluation of development needs, identifying application program interface (API) sources, analytical method development, formulation development and product/technology know-how; and manufacturing of registration batches, studies, dossier compilation for regulatory submission and commercial production. The Company’s therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Blood Related, Cardiac, Gastrointestinal, Gynaecological, Hormones, Neuro / Cns Ophthal / Otologicals, Pain/Analgesics, Respiratory and Vitamins / Minerals / Nutrients.

MANAGEMENT

  • Srinivasa Sadu Chief Executive Officer, Managing Director, Whole-Time Director
  • Ravi Mitra Chief Financial Officer
  • Sampath Kumar Compliance Officer, Company Secretary

Company Summary

GLAND PHARMA SUMMARY

Gland Pharma is trading 0.18% lower at Rs 2130.00 as compared to its last closing price. Gland Pharma has been trading in the price range of 2151.85 & 2121.9. Gland Pharma has given -44.83% in this year & 3.47% in the last 5 days.

 

Gland Pharma has TTM P/E ratio 40.72 as compared to the sector P/E of 25.43. There are 17 analysts who have initiated coverage on Gland Pharma. There are 9 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.

 

The company posted a net profit of 229.45 Crores in its last quarter.

 

Listed peers of Gland Pharma include Alkem Laboratories (0.61%), Biocon (2.23%), Gland Pharma (-0.18%) etc.

FAQs about Gland Pharma

Gland Pharma is trading at 2130.00 as on 4 Oct, 2022 3:29:59 PM. This is -0.18% lower as compared to its previous closing price of 2133.85
The market capitalization of Gland Pharma is 35109.93 Cr as on 4 Oct, 2022 3:29:59 PM.
The average broker rating on Gland Pharma is Buy. The breakup of analyst rating is given below -
  • 2 analysts have given a strong sell rating
  • 2 analysts have given a sell rating
  • 1 analysts have given a hold rating
  • 3 analysts have given a buy rating
  • 9 analysts have given a strong buy rating
The 52 wk high for Gland Pharma is 4074.0 whereas the 52 wk low is 2040.7
Gland Pharma can be analyzed on the following key metrics -
  • TTM P/E: 40.72
  • Sector P/E: 25.43
  • Dividend Yield: 0%
  • D/E ratio: -
Gland Pharma reported a net profit of 1211.66 Cr in 2022.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout